Cargando…

Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV

Vesicular Stomatitis Virus (VSV) is neuropathogenic in rodents but can be attenuated 50-fold by engineering the mouse interferon-beta (IFN-β) gene into its genome. Intravenously administered VSVs encoding IFN-β have potent activity against subcutaneous tumors in the 5TGM1 mouse myeloma model, withou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yarde, Danielle N., Naik, Shruthi, Nace, Rebecca A., Peng, Kah-Whye, Federspiel, Mark J., Russell, Stephen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855306/ https://www.ncbi.nlm.nih.gov/pubmed/24176894 http://dx.doi.org/10.1038/cgt.2013.63

Ejemplares similares

Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy
por: Miller, Amber, et al.
Publicado: (2014)

Curative one-shot systemic virotherapy in murine myeloma
por: Naik, Shruthi, et al.
Publicado: (2012)

Mathematical Model for Radial Expansion and Conflation of Intratumoral Infectious Centers Predicts Curative Oncolytic Virotherapy Parameters
por: Bailey, Kent, et al.
Publicado: (2013)

Potent systemic therapy of Multiple Myeloma utilizing Oncolytic Vesicular stomatitis virus coding for Interferon-beta
por: Naik, Shruthi, et al.
Publicado: (2012)

Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity
por: Ayala Breton, Camilo, et al.
Publicado: (2015)

ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012)

Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
por: Cook, Joselle, et al.
Publicado: (2022)

Oncolytic Viruses: Priming Time for Cancer Immunotherapy
por: Russell, Luke, et al.
Publicado: (2019)

Polycytidine tract deletion from microRNA-detargeted oncolytic Mengovirus optimizes the therapeutic index in a murine multiple myeloma model
por: Penza, Velia, et al.
Publicado: (2022)

A brief review of reporter gene imaging in oncolytic virotherapy and gene therapy
por: Concilio, Susanna C., et al.
Publicado: (2021)

Designing and building oncolytic viruses
por: Maroun, Justin, et al.
Publicado: (2017)

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
por: Kimpel, Janine, et al.
Publicado: (2018)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma
por: Packiriswamy, Nandakumar, et al.
Publicado: (2020)

Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy
por: Ruiz, Autumn J., et al.
Publicado: (2016)

Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP
por: Gautam, Saurabh, et al.
Publicado: (2022)

Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review
por: Moglan, Abdulaziz Molham, et al.
Publicado: (2023)

Construction of VSVΔ51M oncolytic virus expressing human interleukin-12
por: Abdulal, Rwaa H., et al.
Publicado: (2023)

Oncolytic Activity of Targeted Picornaviruses Formulated as Synthetic Infectious RNA
por: Elsedawy, Noura B., et al.
Publicado: (2020)

Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers
por: Melzer, Michael Karl, et al.
Publicado: (2018)

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
por: Kottke, Timothy, et al.
Publicado: (2021)

Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma
por: Krabbe, Teresa, et al.
Publicado: (2021)

Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy
por: Marek, Janina, et al.
Publicado: (2023)

Dual-Isotope SPECT Imaging with NIS Reporter Gene and Duramycin to Visualize Tumor Susceptibility to Oncolytic Virus Infection
por: Zhang, Lianwen, et al.
Publicado: (2019)

Evaluation of the stability and intratumoral delivery of foreign transgenes encoded by an oncolytic Foamy Virus vector
por: Budzik, Karol M., et al.
Publicado: (2022)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
por: Dold, Catherine, et al.
Publicado: (2016)

Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus
por: Liu, Yu-Ping, et al.
Publicado: (2011)

Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H.pylori immunostimulatory bacterial transgene
por: Viker, Kimberly B., et al.
Publicado: (2022)

Oncolytic Foamy Virus: Generation and Properties of a Nonpathogenic Replicating Retroviral Vector System That Targets Chronically Proliferating Cancer Cells
por: Budzik, Karol M., et al.
Publicado: (2021)

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV(POS) Cancers
por: Suksanpaisan, Lukkana, et al.
Publicado: (2018)

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity
por: El-Sayes, Nader, et al.
Publicado: (2022)

MicroRNA-detargeting proves more effective than leader gene deletion for improving safety of oncolytic Mengovirus in a nude mouse model
por: Suryawanshi, Yogesh R., et al.
Publicado: (2021)

Oncolytic Viruses for Multiple Myeloma Therapy
por: Calton, Christine M., et al.
Publicado: (2018)

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
por: Marchica, Valentina, et al.
Publicado: (2021)

Real-time monitoring of oncolytic VSV properties in a novel in vitro microphysiological system containing 3D multicellular tumor spheroids
por: Lee, Kyoung Jin, et al.
Publicado: (2020)

Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9
por: Eckert, Elizabeth C., et al.
Publicado: (2019)

Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
por: Nagalo, Bolni Marius, et al.
Publicado: (2020)

Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
por: Meyers, Daniel E., et al.
Publicado: (2017)

Potential of oncolytic viruses in the treatment of multiple myeloma
por: Bartee, Eric
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vlljh8rpupqg236gov8gtgv6g6